Helicobacter pylori non-invasive testing is basically an infection that occurs in the body when an H. pylori bacterium infects an individual’s stomach. This infection is generally affected to the children and the most common cause of peptic ulcers, H. pylori infection may also be present in above half of the population of the world. Most of the individuals do not realize or realize late that they are suffering from H. pylori since they never experience sickness from the infection. If an individual developed the symptoms and signs of peptic ulcers, the physician will most probably test the individual for H. pylori, and see whether it can be treated through antibiotics.
Helicobacter pylori (H. pylori) non-invasive testing market was estimated to be over US$ 500 Mn in 2018. It is anticipated to grow at a CAGR of 3.8% from 2019 to 2030.
High prevalence rates of helicobacter pylori (H. pylori) globally are expected to fuel the helicobacter pylori (H. pylori) non-invasive testing market during the forecast period. High prevalence rates in turn spur the usage of testing of this bacteria. The helicobacter pylori bacteria grows in the digestive tract and globally is estimated to infect over 50% of the population. In certain countries, the prevalence is estimated to be higher than 80%. In the year 1994, the world health organizations, International Agency for Research on Cancer classified H. pylori as a Class 1 Carcinogen. Low diagnosis rates of helicobacter pylori bacteria are expected to hamper the growth of this market. The diagnosis rates are low as the infection of H. pylori is largely asymptomatic. The infected person does not manifest any marked symptoms.
Major Key Players of the Helicobacter Pylori Non-invasive Testing Market are:
Meridian Bioscience, Inc., DiaSorin S.p.A., Exalenz Bioscience Ltd., Thermo Fisher Scientific, Alere, Certest Biotec S.L, Sekisui Diagnostics, Biomerica, Inc, CorisBioconcept SPRL, and Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. Among others.
No comments:
Post a Comment